

**ROBINS KAPLAN LLP**

Rayna E. Kessler, Esq.  
PA ID No. 309607  
399 Park Avenue, Suite 3600  
New York, New York 10022-4690  
Telephone: (212) 980-7431  
Facsimile: (212) 980-7499  
Email: RKessler@RobinsKaplan.com

Kate Jaycox, Esq. (*Pro hac Vice Motion to be Filed*)  
Caroline Moos, Esq. (*Pro hac Vice Motion to be Filed*)  
2800 LaSalle Plaza  
800 LaSalle Avenue  
Minneapolis, MN 55402-2015  
Telephone: 612-349-8500  
Facsimile: 612-339-4181  
Email: KJaycox@RobinsKaplan.com  
CMoos@RobinsKaplan.com

*Attorneys for Plaintiffs Leah R. Smith and Akida Morgan*

**IN THE UNITED STATES DISTRICT COURT FOR THE  
EASTERN DISTRICT OF PENNSYLVANIA**

**LEAH R. SMITH and  
AKIDA MORGAN,**

*Plaintiffs,*

v.

**LUITPOLD PHARMACEUTICALS, INC.,  
AMERICAN REGENT, INC.,  
DAIICHI SANKYO, INC.,  
DAIICHI SANKYO US HOLDINGS, INC.,  
VIFOR PHARMA LTD.,  
VIFOR PHARMA PARTICIPATIONS LTD.,  
VIFOR (INTERNATIONAL) AG, and  
RELYPSA INC.,**

*Defendants.*

EASTERN DISTRICT OF PENNSYLVANIA

PHILADELPHIA DIVISION

CIVIL ACTION NO. 2:21-cv-00601-WB

Civil Action

*Filed Electronically*

**COMPLAINT**

**AND JURY DEMAND**

Plaintiffs Leah R. Smith and Akida Morgan, by and through their undersigned counsel, bring this civil action against the above-named Defendants for personal injuries and damages, and allege as follows:

**PARTIES**

1. Plaintiffs Leah R. Smith and Akida Morgan reside in Robertsdale, Alabama. Plaintiffs Smith and Morgan are married. Plaintiff Smith suffered serious physical injuries and economic damages due to her use of the injectable iron product, Injectafer (ferric carboxymaltose).

***The American Regent Defendants***

2. Defendant Luitpold Pharmaceuticals, Inc. (“Luitpold”) was a New York corporation. At all relevant times, Luitpold maintained its principal offices in Norristown, Pennsylvania and Shirley, New York and was registered to do business throughout Pennsylvania, including within the county of Philadelphia. Luitpold was the parent to its subsidiary, American Regent, Inc.

3. At all relevant times, and within Pennsylvania, Luitpold engaged in the business of researching, developing, designing, testing, licensing, manufacturing, distributing, supplying, selling, labeling, promoting, marketing, and/or introducing into commerce the Injectafer product. Luitpold was the Sponsor of the New Drug Application (“NDA”) submitted to the FDA on Injectafer in 2013.

4. Defendant American Regent, Inc. (“American Regent”) is a New York corporation. At all relevant times, American Regent had a principal place of business at in Shirley, New York, sharing an office with Luitpold. Upon information and belief, American Regent also operates out of its Norristown, Pennsylvania office and is registered to do business in

Pennsylvania. American Regent was a subsidiary of Luitpold until approximately December 31, 2008.

5. Upon information and belief, on or about December 31, 2008, Luitpold merged American Regent into itself, and the surviving entity – Luitpold – was renamed American Regent.<sup>1</sup> The new entity of American Regent is a wholly owned subsidiary of Daiichi Sankyo, Inc.

6. At all relevant times, and within Pennsylvania, American Regent has engaged in the business of researching, developing, designing, testing, licensing, manufacturing, distributing, supplying, selling, labeling, promoting, marketing, and/or introducing into commerce the Injectafer product.

7. Luitpold was the primary holder of a license to manufacture and market Injectafer from Vifor (International) Inc. until the merger. American Regent is the manufacturer currently listed on the Injectafer label, still under license from Vifor (International) Inc.

8. Upon information and belief, both American Regent and Luitpold were and are part of the Daiichi Sankyo Group.

***The Daiichi Sankyo Defendants***

9. Defendant Daiichi Sankyo, Inc. (“DSI”) is a Delaware corporation with its principal place of business in Basking Ridge, New Jersey. DSI is the United States subsidiary of Daiichi Sankyo Co., Ltd. (“DSC”), located in Tokyo, Japan, and is a member of the Daiichi Sankyo Group. DSI is wholly owned by Defendant Daiichi Sankyo U.S. Holdings, Inc.

10. Defendant Daiichi Sankyo U.S. Holdings, Inc. (“DS Holdings”) is a Delaware

---

<sup>1</sup> Since the merger between Luitpold and American Regent resulted in an entity called American Regent, any allegation throughout the Complaint specific to Luitpold also applies to its successor, American Regent.

corporation with its principal place of business in Basking Ridge, New Jersey. DS Holdings wholly owns DSI. Upon information and belief, DS Holdings is also a subsidiary of DSC and is a member of the Daiichi Sankyo Group.

11. Upon information and belief, DSI is or was also known as Sankyo USA Development, Sankyo Pharma Development, Sankyo Pharma, Inc., Daiichi Sankyo Group, and Daiichi Pharma Holdings, Inc. Upon information and belief, DSI operates as the U.S. headquarters of DSC.

12. At all relevant times, DSI is and was engaged in the business of researching, developing, designing, licensing, manufacturing, distributing, and selling the Injectafer product. Starting in or around January 2017, DSI assumed the role of promoting and marketing Injectafer in the United States.

13. Upon information and belief, at all relevant times, DSI exercised control over the DSI subsidiaries, Luitpold and American Regent, with control over all relevant decisions, policies, and conduct regarding the research, development, design, licensing, manufacture, distribution, marketing, promotion, and selling of Injectafer.

14. Upon information and belief, DS Holdings is and was at all times engaged in the business of researching, developing, designing, licensing, manufacturing, distributing, and selling the Injectafer product.

15. Upon information and belief, DS Holdings exercised ultimate control, and was responsible for the actions and omissions of its wholly owned subsidiary, DSI.

16. Upon information and belief, there existed at all relevant times a unity of interest in ownership between DS Holdings and DSI such that independence from, or separation between, these two Defendants does not and has never existed. Each of them is an alter ego of the other.

17. Because of the unity of operations and ownership, DSI and DS Holdings are hereinafter referred to as the “Daiichi Sankyo Defendants.”

*The Vifor Defendants*

18. Defendant Vifor Pharma Ltd. (“Vifor Pharma”) is a for-profit corporation headquartered, organized, and existing under the laws of Switzerland, with an office location at Rechenstrasse 37 CH-9014 St. Gallen.

19. Defendant Vifor Pharma Participations Ltd. (“Vifor Participations”) is a for-profit corporation headquartered, organized, and existing under the laws of Switzerland, with an office location at Rechenstrasse 37 CH-9014 St. Gallen. Vifor Participations is a wholly owned subsidiary of Vifor Pharma.

20. Defendant Vifor (International) AG a/k/a Vifor (International) Inc. (“Vifor International”) is a for-profit corporation headquartered in Switzerland with an office location at Rechenstrasse 37 CH-9014 St. Gallen. Vifor International is a wholly owned subsidiary of Vifor Participations, Ltd.

21. Defendant Relypsa Inc. (“Relypsa”) is Delaware corporation with its principal office in Redwood City, California. Relypsa Inc. is a wholly owned subsidiary of Vifor Pharma, and a United States Corporate Affiliate of Vifor International.

22. Because of the unity of operations and ownership, Vifor Pharma, Vifor Participations, Vifor International, and Relypsa are hereinafter referred to as the “Vifor Defendants” or “Vifor.”

23. The Vifor Defendants are in the business of researching, developing, designing, licensing, manufacturing, distributing, supplying, selling, marketing, and/or introducing into commerce ferric carboxymaltose, or its European brand bioequivalent, Ferinject.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.